Proteomics in Huntington’s Disease Biomarker Discovery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F23%3A00577184" target="_blank" >RIV/67985904:_____/23:00577184 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/978-3-031-32815-2_9" target="_blank" >http://dx.doi.org/10.1007/978-3-031-32815-2_9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-32815-2_9" target="_blank" >10.1007/978-3-031-32815-2_9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Proteomics in Huntington’s Disease Biomarker Discovery

Popis výsledku v původním jazyce

Mass spectrometry (MS) and proteomics are continuously evolving methods in systems biology that carry enormous potential for accurately profiling the proteome of diseased tissues and exploring biomarker molecules. In Huntington’s disease (HD), the identification of novel effective biomarkers for monitoring the disease progression from the early asymptomatic stage would be extremely useful for clinical decision-making. Although none of the detected candidate molecules has reached the level of validation, available proteomic studies have provided a list of potential protein biomarkers for future targeted studies using modern workflows in large clinical trials. This review summarises protein data from HD patients and experimental models, reporting biomarker candidates verified by independent methods or identified by multiple independent studies. After examining the overlaps across different tissues and models, several known and novel candidates emerged as consistently affected in HD. Based on MS-based HD studies, we propose the monitoring of existing markers mutant Huntingtin (mHTT) and neurofilament light polypeptide (NfL), together with novel candidate markers, such as proenkephalin-A (PENK), proenkephalin-B (PDYN), glial fibrillary acidic protein (GFAP), and many others.

Název v anglickém jazyce

Proteomics in Huntington’s Disease Biomarker Discovery

Popis výsledku anglicky

Mass spectrometry (MS) and proteomics are continuously evolving methods in systems biology that carry enormous potential for accurately profiling the proteome of diseased tissues and exploring biomarker molecules. In Huntington’s disease (HD), the identification of novel effective biomarkers for monitoring the disease progression from the early asymptomatic stage would be extremely useful for clinical decision-making. Although none of the detected candidate molecules has reached the level of validation, available proteomic studies have provided a list of potential protein biomarkers for future targeted studies using modern workflows in large clinical trials. This review summarises protein data from HD patients and experimental models, reporting biomarker candidates verified by independent methods or identified by multiple independent studies. After examining the overlaps across different tissues and models, several known and novel candidates emerged as consistently affected in HD. Based on MS-based HD studies, we propose the monitoring of existing markers mutant Huntingtin (mHTT) and neurofilament light polypeptide (NfL), together with novel candidate markers, such as proenkephalin-A (PENK), proenkephalin-B (PDYN), glial fibrillary acidic protein (GFAP), and many others.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/EF16_019%2F0000785" target="_blank" >EF16_019/0000785: Centrum nádorové ekologie - výzkum nádorového mikroprostředí v organizmu podporujícího růst a šíření nádoru</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Biomarkers for Huntington's Disease

ISBN

978-3-031-32814-5

Počet stran výsledku

38

Strana od-do

209-247

Počet stran knihy

475

Název nakladatele

Springer

Místo vydání

Cham

Kód UT WoS kapitoly

—